30 day mortality following andexanet alfa in annexa-4 compared with prothrombin complex concentrate (pcc) therapy in the orange study for life threatening non-vitamin k oral anticoagulant (noac) related bleeding
Journal of the American College of Cardiology(2020)
摘要
Life-threatening NOAC related major bleeding is associated with high mortality. Off-label PCC is currently recommended in some guidelines as well as the approved specific antidote, andexanet alfa (andexanet). There are no randomised controlled trials comparing these therapies and hence we undertook
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络